Fragile X Syndrome
by Randi Hagerman, M.D.
Professor of Pediatrics, University of Colorado Health Sciences Center
The Children's Hospital
Fragile X syndrome, also known as FXS, is a genetic disorder, which causes a wide range of problems, from learning disabilities or attention deficits to more significant developmental delays or mental retardation. Fragile X syndrome also can cause significant emotional or behavioral problems, including anxiety, panic attacks, and hyperactivity or Attention Deficit Hyperactivity Disorder (ADHD). Fragile X syndrome is the most common cause of inherited mental retardation.
Fragile X syndrome is caused by a mutation in the Fragile X Mental Retardation 1 gene (FMR1), which is located on the bottom end of the X chromosome. The FMR1 gene produces a protein that is important for normal brain development. In studies, where the X chromosome is viewed under the microscope, it narrows at the site of the mutation. This narrowing makes the X chromosome look fragile, as if it would break, hence the name, fragile X syndrome.
The mutation is made up of a repeat of the DNA nucleotide code, CGG. If you think of DNA as a twisted ladder, the nucleotides represent the rungs on the ladder, and, at the FMR1 gene, one side of the ladder has the repetitive CGG sequence. In normal individuals, there are approximately 5 to 50 CGG repeats. In individuals who are carriers of fragile X syndrome, but, usually, are not intellectually affected, the CGG repeat is expanded from approximately 50 to 200 repeats. In individuals who are significantly affected by fragile X syndrome, the CGG repetitions expand to greater than 200, and, sometimes, up to 2,000. This is called the full mutation.
The full mutation undergoes a process of methylation, whereby a methyl group (CH3) is placed on the backbone of the DNA, and the gene is "turned off." Because the gene is turned off, the protein it usually makes is not made. It is the absence-or a deficiency-of the FMR1 protein that causes fragile X syndrome. Some individuals may have cells with the premutation (50 to 200 CGG repeats) and other cells with the full mutation (greater than 200 CGG repeats), so they produce a limited amount of protein, and may be less affected than those individuals who have a full mutation.
Boys are more often affected by fragile X syndrome, because they have only one X chromosome. Their other sex chromosome is Y, which makes them male. If they have a full mutation on their X chromosome, they will be significantly affected by fragile X syndrome. Girls, on the other hand, have two X chromosomes. If a full mutation occurs on only one of them, then their other X chromosome will produce some FMR1 protein, if not a full amount. Thus, they will be less affected, as compared to males. Usually, girls with the full mutation have learning disabilities or attention deficit problems; although, in approximately 70% of cases, their IQ will be either in the borderline range (70 to 85) or in the mildly retarded range (50 to 69).
Both males and females can be carriers of this disorder with the premutation. A CGG expansion to the full mutation only occurs when a woman passes on this mutation to the next generation. Therefore, all children who are affected with fragile X syndrome have a mother who is a carrier. Because she has two X chromosomes (one normal and one premutation), the carrier mother has a 50% chance of passing on the mutation to each of her children. Fragile X syndrome usually affects multiple individuals in a family tree; therefore, genetic counseling is important. A genetic counselor will review the problems of all individuals in an extended family, and will talk with family members who are at risk of being a carrier or affected by this disorder.
The FMR1 mutation causes disease because the CGG expansion in the full mutation range will turn off the gene, which, in turn, prevents the production of the FMR1 protein. The FMR1 protein controls the production of many other messages made by cells in the central nervous system. The FMR1 protein is thought to be important in determining that proper connections are made between nerve cells in early development.
Most children with fragile X syndrome have language delays, i.e., they may not speak in phrases or sentences by 2 or 2 years of age. They also may be hyperactive, inattentive, or impulsive early in childhood, which can lead to a diagnosis of ADHD. Children with FXS are usually extra sensitive to stimuli in their environment, and they frequently have tantrums or emotional outbursts in crowded situations or when making a transition between activities. Shyness or social anxiety may be a common problem; however, initially, many individuals may be shy, and, subsequently, they become impulsive or talkative in social interactions.
Most children with FXS have changes in their connective tissue, such as soft skin, "double-jointed" fingers and thumbs, prominent ears, or a long face. Large testicles are commonly seen in boys with fragile X syndrome; however, this only begins to occur in adolescence or just before the onset of puberty.
Many children may be diagnosed with autistic-like features, such as hand flapping, hand biting, poor eye contact, repetitive speech, and sensitivity to being touched. Approximately 15% of children with FXS also have a diagnosis of autism. These children have more significant social deficits, in addition to shyness. However, most individuals affected by FXS are interested in social interactions and are quite friendly.
Medical problems commonly associated with FXS include recurrent ear infections, perhaps, because of looseness in the connective tissue. This problem is seen in over 60% of cases, and often leads to the placement of pressure equalizing tubes in the eardrums. Rarely, individuals with FXS may have hernias or joint dislocations. Recurrent vomiting is a common problem at the time of birth, and, occasionally, may persist into childhood. Seizures may occur in approximately 20% of patients. Typically, seizures start in early childhood, are usually easily controlled with medication, and often disappear by adolescence or adulthood. Eye problems may be seen in up to 50% of children, including a lazy eye or a need for glasses.
Fragile X syndrome can be diagnosed by two methods; both involve a blood test. The first method is called cytogenetic testing. The white blood cells are grown in a lab to show the fragile site on the bottom end of the X chromosome. Not every individual affected by FXS will show the fragile site on the X chromosome. The second method is called FMR1 DNA testing. This method costs approximately $200, which is less expensive than cytogenetic testing. DNA testing will demonstrate the CGG repeat number at the FMR1 gene. This test will diagnose all individuals affected by fragile X syndrome. It also will identify those individuals who are carriers, which cytogenetic testing does not. DNA testing is the best method of diagnosis. Your doctor can order DNA testing or cytogenetic testing on your child, but all individuals who are suspected of having the Fragile X chromosome should have a DNA test, even if cytogenetic testing was previously performed. Rarely, an individual who is positive on cytogenetic testing may be negative on DNA testing, meaning they do not have a mutation at the FMR1 gene.
All individuals who are affected by FXS require speech and language therapy and occupational therapy, usually with a sensory integration approach. These therapies stimulate and improve motor and language development. In children who have more severe motor problems, treatment by a physical therapist also is necessary.
Most children affected by FXS also will require special education support in school, including individual and/or group tutoring to help academic progress. Children with FXS often have difficulty with math and, sometimes, spelling and reading. Most children can be mainstreamed into a regular classroom; however, they may require an aide to modify regular classroom assignments and to help them complete work.
Medications can be helpful for treating behavior and emotional problems. The use of stimulant medication, such as methylphenidate (Ritalin) and dextroamphetamine (Dexedrine or Adderall), are helpful for the majority of children with FXS who have significant hyperactivity, short attention spans, or impulsive behavior. Usually, these medications are tried at 5 years of age or older; although, occasionally, they can be helpful in the preschool period. Clonidine or guanfacine (Tenex) are medications that can reduce hyperactivity or overstimulation and improve tantrum behavior. These medications can be used after age 3 and, sometimes, can be combined with stimulant medication. The Selective Serotonin Reuptake Inhibitors (SSRIs), such as Prozac, Zoloft, Paxil, or Luvox, can be helpful in treating anxiety, panic attacks, obsessive compulsive behavior, or aggression and outburst behavior. These medications can be used in childhood, adolescence, or adulthood. Sometimes, severe behavioral problems may require the use of an atypical anti-psychotic drug, such as risperidone; however, such a drug should be used in low doses, when necessary.
Medical therapy includes treating associated problems, such as recurrent ear infections. These require the use of either preventive antibiotics or pressure equalizing tubes to ensure that hearing is normalized and not damaged by continued infections. All children with FXS should be seen by an eye doctor to rule out the possibility of a weak eye muscle or the need for glasses, which occurs in approximately 30% to 50% of cases. If orthopedic problems occur, such as recurrent joint dislocations or severe flat feet, an orthopedist should be seen. Severe flat feet may require the use of a shoe insert or high top shoes with a firm arch to provide appropriate support for the foot. Rarely, joint problems may require surgery.
A treatment program should include genetic counseling where parents can review the family tree and determine who is at risk for being a carrier or being affected with FXS. Siblings of a child with FXS should be tested for it with FMR1 DNA testing. Genetic counseling is available to guide prenatal diagnostic procedures, which can identify the degree of the mutation of the fetus at approximately 10 to 15 weeks of pregnancy. Approximately 1 in 200 women in the general population is a carrier of FXS, and approximately 1 in 2,000 women is affected by FXS.
The complications of treating FXS include side effects from the medications that are used. Higher doses of stimulant medication can cause weight loss, sleep disturbances, or high blood pressure. Children who are treated with medications should see their physicians at least 2 to 3 times per year to follow growth parameters and blood pressure. Medications, such as clonidine or guanfacine, can cause significant sedation, and also may require an EKG. The SSRIs can cause gastrointestinal disturbances or diarrhea, which can be improved by adjusting the dosage or changing to a different medication. Careful follow-up with us about side effects can lead to medication changes and improved symptoms.
It is possible to perform prenatal diagnostic testing for FXS using the FMR1 DNA test. If the fetus is positive for the full mutation, the parents can elect to terminate the pregnancy. Such decisions regarding termination or carrying on a pregnancy with a fetus affected with FXS are very personal decisions. The family must make the decision that is right for them. The genetic counselor and the physician will be supportive of the family's decision.
A variety of research projects on fragile X syndrome are being conducted throughout the world. A "knockout mouse model" has been developed where the FMR1 gene is missing. These mice tend to be hyperactive and somewhat learning disabled on psychological tasks. They also have large testicles and changes in their brain, which appear to be similar to humans affected with FXS. The knockout mouse model may be helpful for gene therapy research, where the gene is either replaced or protein is given to the animal to relieve the symptoms. Research also is being conducted on how to "turn on" the gene to produce the FMR1 protein in the nerve cells of FXS patients. Gene replacement therapy or therapy to turn on the gene has not occurred in humans, but it is occurring in test tubes and in animal models.
In addition, research is being performed to determine the best treatments, including medication and educational and/or computer technology, to improve learning in those individuals affected with FXS.
The National Fragile X Foundation
P.O. Box 190488
San Francisco, CA 94119-0488
Phone: (800) 688-8765
FRAXA Research Foundation
P.O. Box 935
West Newbury, MA 01985-0935
Phone: (978) 462-1866
Fragile, Handle With Care: Understanding Fragile X Syndrome. Braden, M. (1997) Chapel Hill: Avanta Publishing. (Can be obtained from The National Fragile X Foundation.)
Fragile X Syndrome: Diagnosis, Treatment and Research, 2nd edition. Hagerman, R.J. and Cronister, A. (eds) (1996) Baltimore: The Johns Hopkins University Press.
Fragile X Syndrome. Hagerman, R.J. (1999) In: "Neurodevelopmental Disorders: Diagnosis and Treatment." New York: Oxford University Press, 61-132.
A Parent's Guide to Drug Treatment of Fragile X Syndrome. Tranfaglia, M.R. (1996) FRAXA Research Foundation, West Newbury, MA.
Transitioning "Special" Children Into Elementary School. Weber, J.D. Books Beyond Borders, Inc., 1881 4th Street, #108, Boulder, CO 80302 (1-800-347-6440).
Boys With Fragile X Syndrome. O'Connor, R. (1995). (Can be obtained from the National Fragile X Foundation.)
My Brother Has Fragile X Syndrome. Steiger, C. (1998) Chapel Hill: Avanta Publishing.
(Can be obtained by calling 1-800-434-0322.)
About the Author
Dr. Hagerman received her M.D. from Stanford Medical School and completed her pediatric residency at Stanford and at the University of California San Diego. She is now a Professor of Pediatrics at the University of Colorado Health Sciences Center and Co-Section Head of Developmental and Behavioral Pediatrics.
Her research interests are in Fragile X Syndrome, Fetal Alcohol Syndrome, organic causes of ADHD and behavioral phenotypes.
Copyright 2012 Randi Hagerman, M.D., All Rights Reserved